U.S. markets close in 1 hour 56 minutes

DermTech, Inc. (DMTK.MX)

Mexico - Mexico Delayed Price. Currency in MXN
Add to watchlist
490.000.00 (0.00%)
As of 12:37PM CST. Market open.

DermTech, Inc.

11099 North Torrey Pines Road
Suite 100
La Jolla, CA 92037
United States
858 450 4222

IndustryDiagnostics & Research
Full Time Employees114

Key Executives

NameTitlePayExercisedYear Born
Dr. John D. DobakPres, CEO & Director667.76kN/A1966
Mr. Kevin Sun M.B.A.CFO, Treasurer & Sec.378.15kN/A1978
Ms. Claudia IbarraChief Operating Officer350.39kN/A1962
Mr. Michael Howell Ph.D.Chief Scientific OfficerN/AN/AN/A
Mr. Ray Akhavan J.D.Gen. CounselN/AN/AN/A
Mr. Ray BassiVP of SalesN/AN/AN/A
Dr. Burkhard JansenChief Medical Affairs OfficerN/AN/A1966
Dr. Zuxu Yao Ph.D.Head of Advanced InnovationN/AN/A1963
Mr. Todd Michael WoodChief Commercial OfficerN/AN/A1969
Mr. Daniel VisageSr. VP of Payer AccessN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in MXN.


DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.

Corporate Governance

DermTech, Inc.’s ISS Governance QualityScore as of September 26, 2021 is 9. The pillar scores are Audit: 9; Board: 9; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.